Table 1.
Antimicrobial regime used | Number of trusts | ||
2005 | 2008 | 2011 | |
Cefuroxime | 121 (79.6%) | 94 (59.9%) | 49 (36.0%) |
Cefuroxime + gentamicin | 2 (1.3%) | 1 (0.6%) | 1 (0.7%) |
Cefuroxime + teicoplanin | 1 (0.7%) | 1 (0.6%) | 1 (0.7%) |
Cefuroxime +/- teicoplanin | – | 1 (0.6%) | 1 (0.7%) |
Cefuroxime + metronidazole | 2 (1.3%) | 1 (0.6%) | – |
Other cephalosporins | 8 (5.3%) | 6 (3.8%) | 2 (1.5%) |
Flucloxacillin | 1 (0.7%) | 2 (1.3%) | 3 (2.2%) |
Flucloxacillin + gentamicin | 2 (1.3%) | 25 (15.9%) | 44 (32.4%) |
Flucloxacillin + benzylpenicillin + gentamicin | – | 1 (0.6%) | 1 (0.7%) |
Teicoplanin | 1 (0.7%) | 1 (0.6%) | 1 (0.7%) |
Teicoplanin + gentamicin | 2 (1.3%) | 5 (3.2%) | 13 (9.6%) |
Co-amoxiclav | 4 (2.6%) | 8 (5.1%) | 11 (8.1%) |
Co-amoxiclav + gentamicin | 1 (0.7%) | 3 (1.9%) | 2 (1.5%) |
Ertapenem | – | 1 (0.6%) | 1 (0.7%) |
Vancomycin | – | – | 1 (0.7%) |
Gentamicin | – | – | 1 (0.7%) |
Vancomycin + gentamicin | 1 (0.7%) | 1 (0.6%) | – |
Cefuroxime or vancomycin | 1 (0.7%) | 1 (0.6%) | 1 (0.7%) |
Cefuroxime or flucloxacillin | 1 (0.7%) | 1 (0.6%) | 1 (0.7%) |
Cefuroxime or co-amoxiclav | 2 (1.3%) | 2 (1.3%) | 1 (0.7%) |
Nil formal | 2 (1.3%) | 2 (1.3%) | 1 (0.7%) |
Total responses | 152 | 157 | 136 |